Follow

The last day of trading with the warrants of series TO1 in 2cureX AB is today, May 5, 2021

05 May 2021 - 08:30

Today, May 5, 2021, is the last day of trading with the warrants of series TO1 in 2cureX AB (“2cureX” or the “Company”). The subscription period for the warrants of series TO1 runs until May 7, 2021. Each warrant of series TO1 gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO1 is SEK 13.22 per share.

Please note that trading and exercise of warrants of series TO1 that are nominee registered must be conducted in accordance with instructions from each respective nominee. Owners of warrants of series TO1 should contact their nominee for further instructions.

Summarized terms for the warrants of series TO1:

Subscription period: April 26 – May 7, 2021.

Issue size: 2,455,000 warrants of series TO1, which entitles to subscription of 2,455,000 shares. If all the warrants are exercised, The Company will receive approximately SEK 32.46 million before issuing costs.

Exercise price: SEK 13.22 per share.

Last day for trading warrants of series TO1: May 5, 2021.

Dilution etc.: If all warrants are exercised the share capital will increase with SEK 245,500.00, from SEK 1,484,600, to SEK 1,730,100. If all warrants are exercised the number of shares will increase with 2,455,000 shares, from 14,846,000 shares, to 17,301,000 shares. The dilution at exercise of all warrants amounts to 14.19 percent of the number of shares and 14.19 percent of the number of votes.

Note that the warrants that are not exercised at the latest May 7, 2021, or sold at the latest May 5, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

The application form including instructions for payment will be available at 2cureX’s website, www.2curex.com and on Mangold Fondkommission AB’s website, www.mangold.se.

Advisers

Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal advisor to 2cureX regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595

E-mail: [email protected]

For more information regarding 2cureX, please contact:
Fernando Andreu
Chief Executive Officer
Tel: +45 22 79 53 99
E-mail: [email protected]

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90

Mail: [email protected]

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
2cureX AB
2cureX is a biotech company. The Company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More